A sourced case for your drug's next disease
A review ranks the diseases your compound has the strongest case for, explains the biology, and shows what happened to other drugs on the same target.
The engagement
You send the compound and the diseases you already plan to pursue. About two weeks later you receive the report, followed by a call to go through it.
- For
- Drug developers with one lead drug
- You receive
- A short PDF report and a call to go through it
- Turnaround
- About two weeks
- Sources
- Peer-reviewed papers, trial registries and company disclosures
- Pricing
- On request
The report, section by section
Every review follows the same order, so the answer is always on the first page.
- SummaryThe recommended disease, a runner-up, one not recommended, the main risk and the first move.
- The drug at a glanceCompany, target, trials, safety, signals, exposure and patent life.
- The biologyWhy the target matters, in plain steps.
- Candidate diseases, rankedEach with its strongest evidence, its biggest weakness and its fit.
- Other drugs on the same targetWhat happened to them, including the failures.
- Risks and open questionsWhere the case is thin, said plainly.
- Recommended next stepsEnding with a kill point: the result that would drop the idea.
- SourcesEvery one linked.
Ready to see where your drug could go next?
Pricing on request. hello@akkadlabs.com